CANY
CTIC

Caxton Associates (New York)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Caxton Associates (New York)’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-55,530
Closed -$332K – 732
2022
Q2 		$332K Buy
55,530
+41,125
+285% +$211K 0.03% 354
2022
Q1 		$67K Buy
+14,405
New +$43K 0.01% 485

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caxton Associates (New York)'s CTIC Position: Q3 2022 in Review

Caxton Associates (New York) sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2022, closing a stake of 55,530 shares — an estimated $332K sold.

Caxton Associates (New York) first reported a position in CTIC in Q1 2022 and held it in 2 quarters. The position peaked at $332K in Q2 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q3 2022.

  • Caxton Associates (New York) reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 55,530 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2022, an estimated $332K.
  • Caxton Associates (New York) first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s CTI BioPharma Corp. (DE) Common Stock position peaked at $332K in Q2 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2022.

Based on Caxton Associates (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.